Side-by-side comparison of AI visibility scores, market position, and capabilities
Veterinary data analytics and client retention platform identifying at-risk patients due for preventive care. Montreal-based; founded 2015;
VetSuccess is a Montreal-based veterinary data analytics and client retention platform that helps veterinary clinics and corporate veterinary groups analyze practice performance data, identify at-risk patients due for preventive care, and automate targeted client communication to improve retention and grow revenue. Founded in 2015, VetSuccess built its platform on a core veterinary insight: the gap between how frequently pets should receive preventive care and how frequently they actually visit the clinic represents a significant and recoverable revenue opportunity for veterinary practices. By analyzing each clinic's patient database against species-specific care protocols, VetSuccess identifies patients overdue for wellness exams, vaccinations, dental cleanings, and parasite prevention—and automates personalized reminder campaigns to bring them back.\n\nVetSuccess's analytics layer provides veterinary practice owners and managers with benchmarked performance metrics covering active client counts, average transaction value, compliance rates for key services, and retention cohort analysis. This data-driven view allows practices to understand not just what happened last month but how their performance trends compare to regional and national benchmarks, identifying specific service lines or client segments where improvement opportunities exist. The platform's corporate dashboard tier serves multi-location veterinary groups and corporate consolidators that need consistent analytics and benchmarking across dozens of practices.\n\nVetSuccess has built a particular strength in the corporate veterinary market, where large veterinary groups and private equity-backed consolidators require standardized performance management across their clinic portfolios. The company serves clients across Canada and the United States and has integrated its platform with major veterinary practice management systems including IDEXX Cornerstone, AVImark, and ezyVet. VetSuccess competes with Covetrus, Rapport, and Vet Hero in the veterinary client communication and analytics market, differentiating on the depth of its analytics and its strong corporate veterinary customer segment.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.